Klacid I.V.

Clarithromycin, the active ingredient in Klacid I.V., is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats serious bacterial infections in adults and children as prescribed.

GNH USA supplies Klacid I.V. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Clarithromycin is a macrolide antibiotic used to treat infections caused by susceptible bacteria.

- Community-acquired pneumonia: effective against typical and atypical pathogens to improve respiratory symptoms. - Skin and soft‑tissue infections: helps eradicate susceptible Gram‑positive and some Gram‑negative organisms. - Intra‑abdominal infections: targets mixed flora in peritonitis and postoperative infections. - Severe bacterial infections in hospitalized patients: provides high plasma concentrations for rapid bacterial control.

Adverse reactions may occur with clarithromycin intravenous therapy.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Altered taste perception - Headache - Vomiting

Serious or Rare Side Effects: - Hepatic dysfunction or elevated liver enzymes - QT‑interval prolongation leading to arrhythmias - Severe allergic reactions including anaphylaxis - Clostridioides difficile‑associated colitis - Severe skin reactions such as Stevens‑Johnson syndrome - Hematologic abnormalities (e.g., neutropenia).

When using Klacid I.V., clinicians should consider several safety measures.

- Renal or hepatic impairment: adjust dosing and monitor function. - Cardiac risk: monitor QT interval, especially in patients with known prolongation. - Known macrolide allergy: avoid use to prevent hypersensitivity. - Concomitant medications: review for potential drug‑drug interactions. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at room temperature: keep in the original pack, protect from moisture and light.

Clarithromycin can interact with several drug classes.

Major Interactions (Avoid): - Cisapride, pimozide, and other QT‑prolonging agents: risk of serious arrhythmias. - Simvastatin, lovastatin: increased statin exposure may cause rhabdomyolysis. - Certain anti‑arrhythmic drugs (e.g., quinidine): may lead to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin and other anticoagulants: may enhance anticoagulant effect. - Carbamazepine, phenytoin: clarithromycin may increase plasma levels. - Digoxin: monitor serum concentrations for possible increase.